Cannabis Meets Drug Metabolism: What We Know and What We Don’t About Cannabinoids and CYP450 Enzymes

A 2025 narrative review published in Frontiers in Pharmacology maps the existing evidence on how THC, CBD, and related cannabinoid compounds may alter cytochrome P450 enzyme activity and drug metabolism, while highlighting substantial gaps in the translation from preclinical findings to clinically actionable knowledge.

Why This Matters

Cannabis use, both medical and recreational, is expanding rapidly worldwide, and a growing number of patients now combine cannabinoids with prescription medications metabolized by the same liver enzyme systems. Cytochrome P450 enzymes are responsible for processing the majority of commonly prescribed drugs, making any interference with their activity a serious safety concern. Clinicians urgently need reliable data on cannabinoid-drug interactions to guide prescribing decisions, but the research base has remained fragmented and largely preclinical. This review arrives at a moment when regulatory agencies and practitioners alike are asking for clearer pharmacovigilance guidance.

Clinical Summary

Cannabinoids interact with the body’s drug-metabolizing machinery through a family of liver enzymes known as the cytochrome P450 (CYP450) system. A 2025 narrative review by researchers at Masaryk University, published in Frontiers in Pharmacology, synthesizes in vitro, animal, and limited human evidence on how THC, CBD, cannabigerol (CBG), endocannabinoids, and synthetic cannabinoids modulate key CYP450 isoforms, particularly CYP3A4, CYP2C9, and CYP1A2. The mechanistic basis is straightforward: if cannabinoids inhibit or induce these enzymes, they could raise or lower plasma concentrations of co-administered drugs, potentially causing toxicity or therapeutic failure. The review also introduces a more speculative hypothesis, proposing that cannabinoids may indirectly regulate CYP450 activity through effects on neuronal circuits such as the locus coeruleus and raphe nuclei, as well as the hypothalamic-pituitary-adrenal (HPA) axis.

In vitro and animal data consistently show that CBD and THC can inhibit several clinically relevant CYP450 isoforms, though effect magnitudes and dose-response relationships in humans remain undefined. The neuroendocrine regulatory hypothesis, while intellectually interesting, lacks direct experimental confirmation. Critically, this is a narrative review with no registered protocol and no systematic search methodology, meaning its literature coverage cannot be independently verified and selection bias cannot be excluded. The authors acknowledge that well-controlled human pharmacokinetic studies are needed before these findings can support clinical dosing recommendations or formal drug interaction guidelines.

Dr. Caplan’s Take

This review addresses something I encounter constantly: patients using cannabis alongside prescription medications and asking whether there is a problem. The honest answer remains that we have strong mechanistic reasons to suspect interactions, particularly with CBD at therapeutically relevant doses, but we do not have the rigorous human pharmacokinetic data to quantify those risks for most drug combinations. The neuroendocrine hypothesis the authors propose is creative and worth pursuing, but it is far from clinically actionable. What this paper really highlights is a gap, not a conclusion.

In practice, I treat cannabinoid-drug interactions as a real concern, especially for patients on narrow therapeutic index medications like warfarin, certain antiepileptics, and immunosuppressants. I monitor drug levels more closely in these patients, counsel them about the possibility of altered medication effects, and document the cannabinoid use in their records. Until we have the controlled human data this field needs, careful monitoring and transparent patient communication remain the most defensible approach.

Clinical Perspective

This review sits at an early stage of the research arc. It usefully consolidates scattered preclinical evidence showing that cannabinoids can modulate CYP450 isoform activity, and it correctly identifies this as a pharmacovigilance priority. However, it does not perform a systematic search, does not quantify effect sizes, and does not distinguish between concentrations achievable in human plasma and those used in in vitro assays, a critical distinction for clinical translation. The evidence does not yet support specific dose-adjustment recommendations for any cannabinoid-drug pair beyond the limited data available for pharmaceutical-grade CBD (Epidiolex) interactions with clobazam and valproate. Clinicians should not assume that all cannabinoid products carry the same interaction profile.

From a safety standpoint, CBD is the cannabinoid most consistently implicated in CYP450 inhibition at clinically relevant concentrations, particularly affecting CYP3A4 and CYP2C19. Patients on substrates of these enzymes, including many statins, benzodiazepines, certain SSRIs, and calcineurin inhibitors, warrant closer monitoring if they initiate or change CBD use. One concrete recommendation clinicians can implement now: when a patient reports regular cannabinoid use, flag the CYP450-mediated medications in their regimen, increase therapeutic drug monitoring frequency where available, and document both the cannabinoid product and approximate dose in the medical record.

Study at a Glance

Study Type

Narrative review

Population

Not applicable (synthesis of in vitro, preclinical animal, and limited human studies)

Intervention

Cannabinoids including THC, CBD, CBG, endocannabinoids, and synthetic cannabinoids

Comparator

Not applicable

Primary Outcomes

CYP450 isoform modulation (inhibition or induction) and potential drug-drug interactions

Sample Size

Not applicable (narrative review)

Journal

Frontiers in Pharmacology

Year

2025

DOI

10.3389/fphar.2025.1599012

Funding Source

Not reported

What Kind of Evidence Is This

This is a narrative review published in an open-access peer-reviewed journal. Narrative reviews occupy a lower tier of the evidence hierarchy than systematic reviews or meta-analyses because they lack a registered protocol, predefined inclusion criteria, and reproducible search methodology. The single most important inference constraint this design imposes is that the authors selected which studies to include, meaning the evidence base may not be comprehensive and selection bias cannot be excluded. The conclusions should be read as hypothesis-generating rather than definitive.

How This Fits With the Broader Literature

The finding that CBD and THC can inhibit CYP450 isoforms in vitro is consistent with earlier work, including a well-cited 2020 review by Nasrin and colleagues examining cannabinoid-drug interactions through the CYP450 lens, as well as pharmacokinetic data generated during Epidiolex development showing clinically meaningful interactions between pharmaceutical CBD and clobazam. This review extends the conversation by proposing an indirect neuroendocrine mechanism for CYP450 regulation, a hypothesis that does not yet appear in established pharmacology literature for cannabinoids. The broader literature confirms that cannabinoid-drug interaction research remains heavily weighted toward in vitro and animal models, with very few well-powered human pharmacokinetic studies available for most cannabinoid-drug combinations.

Common Misreadings

The most likely overinterpretation is concluding that cannabinoids cause dangerous drug interactions across the board and that all patients combining cannabis with prescription medications face immediate clinical risk. While the preclinical evidence shows that cannabinoids can modulate CYP450 enzymes, the concentrations used in many in vitro studies may exceed what is achievable in human plasma at typical dosing. Without controlled human pharmacokinetic data for specific drug pairs, the magnitude and clinical relevance of most interactions remain unknown. Clinicians should not dismiss the risk, but neither should they treat it as confirmed at the bedside for all combinations.

Bottom Line

This narrative review usefully consolidates preclinical evidence that cannabinoids, particularly CBD and THC, can modulate CYP450 enzyme activity in ways that could alter the metabolism of co-administered drugs. It does not establish clinical effect sizes, does not perform a systematic search, and introduces a neuroendocrine hypothesis that remains unconfirmed. For practice now, the review reinforces the need for heightened pharmacovigilance and therapeutic drug monitoring when patients use cannabinoids alongside CYP450-metabolized medications, while we await the rigorous human data this field still lacks.

References

1. Narrative review on cannabinoids and CYP450 enzyme interactions. Frontiers in Pharmacology. 2025. DOI: 10.3389/fphar.2025.1599012.
2. Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P. Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions. Clinical Pharmacology and Therapeutics. 2021;109(6):1506-1517.
3. Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586-1592.